InstantGMP, a leader in fully integrated GMP-compliant software solutions for pharmaceutical manufacturing, has partnered with Corsair Pharma, an innovative biopharmaceutical company focused on enhancing the effectiveness of medications to create improved treatment options for patients with complex medical needs.

As Corsair prepares for Phase One clinical trials of its first product candidate—a prodrug of Treprostinil delivered via a proprietary transdermal—it’s prioritizing safety, tolerability, and quality at every stage of development. To support these critical goals, the company has transitioned from a paper-based system to InstantGMP’s Quality Management System (QMS) and Document Management System (DMS) modules.

InstantGMP’s integrated quality and document management systems offer Corsair Pharma significant benefits, including rigorous quality assurance, reduced errors and rework, improved process controls, streamlined regulatory compliance (US, UK, and European), and enhanced traceability and supplier management. The document management system further centralizes all production-related files for efficient organization and streamlines process connectivity by linking documents across workflows for quick reviews, updates, and approvals.

“As Corsair Pharma transitions into Phase One clinical trials, safety and quality are our highest priorities,” said Jason Vines, Quality Manager at Corsair Pharma. “InstantGMP’s QMS and DMS modules provide us with the tools we need to ensure safety, maintain compliance, streamline our operations, and focus on delivering transformative solutions for our patients. We’re confident that this partnership will be instrumental in our success.”

Dive Deeper

Learn more about Quality Management Systems: The Future of Quality Oversight.